CRISPR Therapeutics
CRSP
Market cap $5.1B

59.02 USD

-4.73

7.42%

At close Jul 29, 4:00 PM EDT

After hours

59.24

+0.22

0.37%

1 day

-7.42%

5 days

-13.09%

1 month

21.34%

3 months

57.81%

6 months

43.22%

Year to date

42.46%

1 year

0.89%

5 years

-30.99%

10 years

318.88%

About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Employees: 393

Healthcare Biotechnology

Funds holding %

of 7,323 funds

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]

27% more call options, than puts

Call options by funds: $96.3M | Put options by funds: $75.6M

17% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 102

0.79% less ownership

Funds ownership: 75.6% [Q4 2024] → 74.81% (-0.79%) [Q1 2025]

3% less funds holding

Funds holding: 397 [Q4 2024] → 385 (-12) [Q1 2025]

10% less first-time investments, than exits

New positions opened: 53 | Existing positions closed: 59

14% less capital invested

Capital invested by funds: $2.54B [Q4 2024] → $2.19B (-$355M) [Q1 2025]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$42

29%

downside

Avg. target

$70

19%

upside

High target

$105

78%

upside

9 analyst ratings

6 positive

67%

3 neutral

33%

0 negative

B of A Securities Geoff Meacham	32%upside $78	Buy Maintained	22 Jul 2025
Needham Gil Blum	37%upside $81	Buy Reiterated	8 Jul 2025
Clear Street Bill Maughan	24%downside $45	Hold Downgraded	27 Jun 2025
Piper Sandler Edward Tenthoff	78%upside $105	Overweight Reiterated	27 Jun 2025
JMP Securities Silvan Tuerkcan	46%upside $86	Market Outperform Reiterated	27 Jun 2025